Literature DB >> 6300231

Patterns of isotype commitment in human B cells: limiting dilution analysis of Epstein Barr virus-infected cells.

L D Stein, C J Ledgley, N H Sigal.   

Abstract

The frequency of Epstein Barr virus- (EBV) inducible IgM, IgG, and IgA-secreting cells in human peripheral blood and tonsil was determined by performing limiting dilution experiments in suspension culture. We devised a method of propagating small numbers of EBV-infected B cells with irradiated umbilical cord blood cells as a feeder layer. Precursor cell frequencies can be derived from these experiments; we have shown by statistical analysis that they conform to the single hit model of the Poisson distribution. By using this technique, a significant percentage of surface immunoglobulin-bearing lymphocytes are activated to secrete immunoglobulin in vitro. On the average, 8 to 38% of B cells in peripheral blood and tonsil can be propagated and the secreted immunoglobulin from the clonal progeny can be analyzed. Neither the EBV immune status of the donor nor the source of the umbilical cord blood feeder layer could account for the variations in cloning efficiency observed among donors. A surprisingly high frequency of B cells secreted IgA in vitro and we have shown that a small proportion of B cell clones in tonsil and peripheral blood secrete both IgM and IgA during the 4-wk culture period. Other B cells, including all those that produce IgG, appear to be committed to the secretion of a single isotype. Thus, these studies establish methodology for the analysis of the secreted products of human B cells at the single cell level and demonstrate that the progeny of at least some clones can secrete more than one isotype in vitro.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6300231

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Self-reactive B lymphocytes detected in young adults, children and newborns after in vitro infection with Epstein-Barr virus.

Authors:  H Uhlig; G Rutter; R Dernick
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

2.  Nonrandom X chromosome inactivation in B cells from carriers of X chromosome-linked severe combined immunodeficiency.

Authors:  M E Conley; A Lavoie; C Briggs; P Brown; C Guerra; J M Puck
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

3.  Efficient generation in vitro, from human peripheral blood cells, of monoclonal Epstein-Barr virus transformants producing specific antibody to a variety of antigens without prior deliberate immunization.

Authors:  L Winger; C Winger; P Shastry; A Russell; M Longenecker
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

4.  Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function.

Authors:  L M Pilarski; E J Andrews; M J Mant; B A Ruether
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

5.  Abnormal function of B lymphocytes from peripheral blood of multiple myeloma patients. Lack of correlation between the number of cells potentially able to secrete immunoglobulin M and serum immunoglobulin M levels.

Authors:  L M Pilarski; B A Ruether; M J Mant
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

6.  Epstein-Barr-virus-transformed lymphoblastoid cell lines derived from patients with X-linked agammaglobulinaemia and Wiskott-Aldrich syndrome: responses to B cell growth and differentiation factors.

Authors:  Y L Lau; J G Shields; R J Levinsky; R E Callard
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

Review 7.  Human monoclonal antibodies.

Authors:  S P Cole; B G Campling; T Atlaw; D Kozbor; J C Roder
Journal:  Mol Cell Biochem       Date:  1984-06       Impact factor: 3.396

8.  Specificity repertoire of lymphocytes from multiple myeloma patients. I. High frequency of B cells specific for idiotypic and F(ab')2-region determinants on immunoglobulin.

Authors:  L M Pilarski; M Piotrowska-Krezolak; D J Gibney; L Winger; C Winger; M J Mant; B A Ruether
Journal:  J Clin Immunol       Date:  1985-07       Impact factor: 8.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.